Search clinical trials for: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)

Total 10 results

Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Buddhist Tzu Chi General Hospital

Unknown

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Overactive Bladder Syndrome

Taiwan
Chang Gung Memorial Hospital

Unknown

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Overactive Bladder Syndrome | Detrusor Overactivity
Beni-Suef University

Completed

Compare Sudden Stopping and Weaning of Anticholinergics in Recurrence of OAB Symptoms

Voiding Disorders

Egypt
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Mansoura University

Recruiting

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Ureteral Stent | Stent Related Symptoms

Egypt
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Completed

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Overactive Bladder

Bangladesh
Xing Liu

Completed

Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children

Overactive Bladder

China
Seoul National University Hospital
Il-Yang Pharm. Co., Ltd.

Not yet recruiting

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Overactive Bladder

Korea, Republic of

3

Subscribe